ArriVent BioPharma, Inc. Sample Contracts
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • February 3rd, 2025 • ArriVent BioPharma, Inc. • Pharmaceutical preparations • New York
ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to the Maximum Program Amount (as defined below) on the terms set forth in this agreement (this “Agreement”).
ArriVent BioPharma, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 22nd, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
Goldman Sachs & Co. LLC Jefferies LLC Citigroup Global Markets Inc. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto,
Indemnification AgreementIndemnification Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made and entered into this [__]th day of [____], 202[ ], by and between ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and [___________] (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 16, 2022, by and among ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with offices located at 18 Campus Blvd. Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”). ArriVent and Aarvik are referred to herein individually, as a “Party” or, collectively, as “Parties.”
CLINICAL COLLABORATION AGREEMENTClinical Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York
This CLINICAL COLLABORATION AGREEMENT (this “Agreement”) is entered into as of June 23, 2023 (the “Effective Date”), by and between ArriVent BioPharma Inc., having an address at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”), and Beijing InnoCare Pharma Tech Co., Ltd., having an address at Building 8, No. 8 Life Science Park Road, ZGC Life Science Park, Changping District, Beijing, China 102206 (“InnoCare”). ArriVent and InnoCare are each referred to herein individually as “Party” and collectively as “Parties”.
JOINT CLINICAL COLLABORATION AGREEMENTJoint Clinical Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
This Joint Clinical Collaboration Agreement (the “Collaboration Agreement”), dated and effective as of [DATE] (the “Effective Date”), is by and between Shanghai Allist Pharmaceuticals Co., Ltd., (“Allist”) a limited liability company incorporated under the laws of China, having its principal place of business at No. 1118 Halei Road, Pudong New District, Shanghai, China; and ArriVent BioPharma, Inc. (“ArriVent”), a Delaware corporation, at 18 Campus Blvd. Suite 100, Newport P.A. (each a Party; collectively, Parties.)
GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT between ArriVent Biopharma, Inc. and Shanghai Allist Pharmaceuticals Co., Ltd.Global Technology Transfer and License Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
This GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (this “Agreement”) is effective from the Effective Date by and between:
RESEARCH AND COLLABORATION AGREEMENT BETWEEN JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD AND ARRIVENT BIOPHARMA, INC. June 2, 2024Research and Collaboration Agreement • August 14th, 2024 • ArriVent BioPharma, Inc. • Pharmaceutical preparations
This RESEARCH AND COLLABORATION AGREEMENT (this “Agreement”) is made and entered into on June 2, 2024 (the “Effective Date”), by and between JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD, with a place of business at No. 175 Fangzhou Road, SIP, Suzhou, Jiangsu, P.R. China 215125 (“Alphamab”), and ARRIVENT BIOPHARMA, INC., with a place of business at 18 Campus Blvd, Suite 100, Newtown Square, PA 19073-3269, United States (“ArriVent”). Alphamab and ArriVent may be referred to herein individually as a “Party” and collectively as the “Parties.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 12th, 2025 • ArriVent BioPharma, Inc. • Pharmaceutical preparations
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of January 21, 2025 (the “Effective Date”) by and between LEPU BIOPHARMA CO., LTD., a corporation organized and existing under the laws of the People’s Republic of China and having a place of business at No. 651 Lianheng Road, Minhang District, Shanghai, China (“Lepu”), and ARRIVENT BIOPHARMA, INC., a corporation organized and existing under the laws of the state of Delaware, U.S. and having a place of business at 18 Campus Blvd, Suite 100, Newtown Square, PA 19073- 3269, United States (“ArriVent”). Lepu and ArriVent are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • November 14th, 2024 • ArriVent BioPharma, Inc. • Pharmaceutical preparations
This AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of August 9, 2024 (the “Restated Agreement Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent BioPharma, Inc., a company incorporated in Delaware, with offices located at 18 Campus Blvd. Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”). ArriVent and Aarvik are referred to herein individually, as a “Party” or, collectively, as “Parties.”
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • November 10th, 2025 • ArriVent BioPharma, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 TO THE AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENT (this “Amendment”) is effective as of July 2, 2025 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent BioPharma, Inc., a company incorporated in Delaware, with offices located at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”). ArriVent and Aarvik are referred to herein individually as a “Party” or, collectively, as the “Parties.”
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 11th, 2025 • ArriVent BioPharma, Inc. • Pharmaceutical preparations
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 11th, 2026 • ArriVent BioPharma, Inc. • Pharmaceutical preparations • New York
This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 5th day of March, 2026 by and between SILICON VALLEY BANK, A DIVISION OF